Effects of gabapentin on experimental somatic pain and temporal summation.
OBJECTIVE
Gabapentin is used for treatment of neuropathic pain, but its effect on different somatic pain modalities and integrative mechanisms are not completely understood. The aim of this double-blind, placebo-controlled experimental pain study, conducted on 20 healthy volunteers, was to examine the effect of a single dose of 1200 mg gabapentin on multi-modal experimental cutaneous and muscle pain models.


METHODS
The following pain models were applied: (1) pain thresholds to single and repeated cutaneous and intramuscular electrical stimulation (temporal summation to 5 stimuli delivered at 2 Hz); (2) stimulus-response function relating pain intensity scores (visual analog scale, VAS) to increasing current intensities for electrical skin and muscle stimuli (single and repeated, determined at baseline); and (3) the pain intensity (VAS) and pain areas after intramuscular injection of hypertonic saline. Pain assessments were performed prior to, and at 4, 6, and 8 hours after medication.


RESULTS
When responses were averaged across the post-dose times, gabapentin: (1) significantly increased the temporal summation pain threshold in skin compared with placebo (P = .03); (2) significantly reduced the area under the pain intensity curve to hypertonic saline injections in the muscle (P = .02); and (3) significantly reduced the area of pain evoked by hypertonic saline (P = .03).


CONCLUSIONS
Gabapentin reduces temporal summation of skin stimuli at pain threshold intensities; this may have potential as a biomarker for drugs with efficacy on neurogenic pain. The data also suggest that tonic muscle pain is responsive to gabapentin treatment and suggest further clinical studies.
Arendt-Nielsen
Lars
L
Center for Sensory-Motor Interactions, Department of Health Science and Technology, Aalborg University, Denmark. LAN@hst.aau.dk
Frøkjaer
Jens Brøndum
JB
Staahl
Camilla
C
Graven-Nielsen
Thomas
T
Huggins
John P
JP
Smart
Trevor S
TS
Drewes
Asbjørn Mohr
AM
D000328:Adult; D000588:Amines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000700:Analgesics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003509:Cyclohexanecarboxylic Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004311:Double-Blind Method; D004558:Electric Stimulation; D000077206:Gabapentin; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000473:pathology; D009619:Nociceptors / Q000187:drug effects; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy* / Q000523:psychology; D010147:Pain Measurement / Q000187:drug effects; D017288:Pain Threshold / Q000187:drug effects; D012867:Skin / Q000473:pathology; D005680:gamma-Aminobutyric Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin